Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

Table 1 Characteristics of patients and outcomes after ATO treatment

Patient no.	Age/gender	Time since diagnosis (months)	Previous Courses of intensive IST^*(months)	Time since last intensive IST (months)	Response to prior intensive IST	Time to initial response to ATO (days)	Time to maximum response to ATO (days)	The final response to ATO	Present status
1	21/M	35	2	9.8	Primary refractory^#	41	56	CR	CR and well 34 months
2	37/F	71	1	11	Relapsed refractory^†	43	102	PR	PR and well 28 months
3	43/M	38	2	13.4	Primary refractory	42	87	CR	CR and well 25 months
4	35/F	41	2	9.2	Primary refractory	46	69	CR	Relapsed and transfusion dependent
5	29/M	63	2	10.3	Primary refractory	48	108	PR	PR and well 20 months

M, male; F, female; IST, Intensive immunosuppressive therapy; ATO, arsenic trioxide; CR, complete response; PR, partial response.
^*IST regimens included horse antithymocyte globulin (ATG), rabbit ATG, cyclophosphamide, and fludarabine.
^#Primary refractory disease was defined as no prior adequate response to IST.
^†Relapsed refractory disease was defined as a prior adequate response to at least one regimen of IST.

ISSN: 1756-8722